Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants

Hongmei Nan; Carolyn M. Hutter; Yi Lin; Eric J. Jacobs; Cornelia M. Ulrich; Emily White; John A. Baron; Sonja I. Berndt; Hermann Brenner; Katja Butterbach; Bette J. Caan; Peter T. Campbell; Christopher S. Carlson; Graham Casey; Jenny Chang-Claude; Stephen J. Chanock; Michelle Cotterchio; David Duggan; Jane C. Figueiredo; Charles S. Fuchs; Edward L. Giovannucci; Jian Gong; Robert W. Haile; Tabitha A. Harrison; Richard B. Hayes; Michael Hoffmeister; John L. Hopper; Thomas J. Hudson; Mark A. Jenkins; Shuo Jiao; Noralane M. Lindor; Mathieu Lemire; Loic Le Marchand; Polly A. Newcomb; Shuji Ogino; Bethann M. Pflugeisen; John D. Potter; Conghui Qu; Stephanie A. Rosse; Anja Rudolph; Robert E. Schoen; Fredrick R. Schumacher; Daniela Seminara; Martha L. Slattery; Stephen N. Thibodeau; Fridtjof Thomas; Mark Thornquist; Greg S. Warnick; Brent W. Zanke; W. James Gauderman; Ulrike Peters; Li Hsu; Andrew T. Chan

doi:10.1001/jama.2015.1815

Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants

Hongmei Nan, Carolyn M. Hutter, Yi Lin, Eric J. Jacobs, Cornelia M. Ulrich, Emily White, John A. Baron, Sonja I. Berndt, Hermann Brenner, Katja Butterbach, Bette J. Caan, Peter T. Campbell, Christopher S. Carlson, Graham Casey, Jenny Chang-Claude, Stephen J. Chanock, Michelle Cotterchio, David Duggan, Jane C. Figueiredo, Charles S. FuchsEdward L. Giovannucci, Jian Gong, Robert W. Haile, Tabitha A. Harrison, Richard B. Hayes, Michael Hoffmeister, John L. Hopper, Thomas J. Hudson, Mark A. Jenkins, Shuo Jiao, Noralane M. Lindor, Mathieu Lemire, Loic Le Marchand, Polly A. Newcomb, Shuji Ogino, Bethann M. Pflugeisen, John D. Potter, Conghui Qu, Stephanie A. Rosse, Anja Rudolph, Robert E. Schoen, Fredrick R. Schumacher, Daniela Seminara, Martha L. Slattery, Stephen N. Thibodeau, Fridtjof Thomas, Mark Thornquist, Greg S. Warnick, Brent W. Zanke, W. James Gauderman, Ulrike Peters, Li Hsu, Andrew T. Chan

Research output: Contribution to journal › Article › peer-review

162 Scopus citations

Abstract

IMPORTANCE Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with lower risk of colorectal cancer. OBJECTIVE To identify common genetic markers that may confer differential benefit from aspirin or NSAID chemoprevention, we tested gene × environment interactions between regular use of aspirin and/or NSAIDs and single-nucleotide polymorphisms (SNPs) in relation to risk of colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS Case-control study using data from 5 case-control and 5 cohort studies initiated between 1976 and 2003 across the United States, Canada, Australia, and Germany and including colorectal cancer cases (n=8634) and matched controls (n=8553) ascertained between 1976 and 2011. Participants were all of European descent. EXPOSURES Genome-wide SNP data and information on regular use of aspirin and/or NSAIDs and other risk factors. MAIN OUTCOMES AND MEASURES Colorectal cancer. RESULTS Regular use of aspirin and/or NSAIDs was associated with lower risk of colorectal cancer (prevalence, 28%vs 38%; odds ratio [OR], 0.69 [95%CI, 0.64-0.74]; P = 6.2 × 10-28) compared with nonregular use. In the conventional logistic regression analysis, the SNP rs2965667 at chromosome 12p12.3 near the MGST1 gene showed a genome-wide significant interaction with aspirin and/or NSAID use (P = 4.6 × 10-9 for interaction). Aspirin and/or NSAID use was associated with a lower risk of colorectal cancer among individuals with rs2965667-TT genotype (prevalence, 28%vs 38%; OR, 0.66 [95%CI, 0.61-0.70]; P = 7.7 × 10-33) but with a higher risk among those with rare (4%) TA or AA genotypes (prevalence, 35%vs 29%; OR, 1.89 [95%CI, 1.27-2.81]; P = .002). In case-only interaction analysis, the SNP rs16973225 at chromosome 15q25.2 near the IL16 gene showed a genome-wide significant interaction with use of aspirin and/or NSAIDs (P = 8.2 × 10-9 for interaction). Regular use was associated with a lower risk of colorectal cancer among individuals with rs16973225-AA genotype (prevalence, 28%vs 38%; OR, 0.66 [95%CI, 0.62-0.71]; P = 1.9 × 10-30) but was not associated with risk of colorectal cancer among those with less common (9%) AC or CC genotypes (prevalence, 36% vs 39%; OR, 0.97 [95%CI, 0.78-1.20]; P = .76). CONCLUSIONS AND RELEVANCE In this genome-wide investigation of gene × environment interactions, use of aspirin and/or NSAIDs was associated with lower risk of colorectal cancer, and this association differed according to genetic variation at 2 SNPs at chromosomes 12 and 15. Validation of these findings in additional populations may facilitate targeted colorectal cancer prevention strategies.

Original language	English (US)
Pages (from-to)	1133-1142
Number of pages	10
Journal	JAMA - Journal of the American Medical Association
Volume	313
Issue number	11
DOIs	https://doi.org/10.1001/jama.2015.1815
State	Published - Mar 17 2015
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1001/jama.2015.1815

Cite this

Nan, H., Hutter, C. M., Lin, Y., Jacobs, E. J., Ulrich, C. M., White, E., Baron, J. A., Berndt, S. I., Brenner, H., Butterbach, K., Caan, B. J., Campbell, P. T., Carlson, C. S., Casey, G., Chang-Claude, J., Chanock, S. J., Cotterchio, M., Duggan, D., Figueiredo, J. C., ... Chan, A. T. (2015). Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA - Journal of the American Medical Association, 313(11), 1133-1142. https://doi.org/10.1001/jama.2015.1815

Nan, H, Hutter, CM, Lin, Y, Jacobs, EJ, Ulrich, CM, White, E, Baron, JA, Berndt, SI, Brenner, H, Butterbach, K, Caan, BJ, Campbell, PT, Carlson, CS, Casey, G, Chang-Claude, J, Chanock, SJ, Cotterchio, M, Duggan, D, Figueiredo, JC, Fuchs, CS, Giovannucci, EL, Gong, J, Haile, RW, Harrison, TA, Hayes, RB, Hoffmeister, M, Hopper, JL, Hudson, TJ, Jenkins, MA, Jiao, S, Lindor, NM, Lemire, M, Le Marchand, L, Newcomb, PA, Ogino, S, Pflugeisen, BM, Potter, JD, Qu, C, Rosse, SA, Rudolph, A, Schoen, RE, Schumacher, FR, Seminara, D, Slattery, ML, Thibodeau, SN, Thomas, F, Thornquist, M, Warnick, GS, Zanke, BW, Gauderman, WJ, Peters, U, Hsu, L & Chan, AT 2015, 'Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants', JAMA - Journal of the American Medical Association, vol. 313, no. 11, pp. 1133-1142. https://doi.org/10.1001/jama.2015.1815

@article{bc9aa5b8af1940af8562c6d111a45533,

title = "Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants",

abstract = "IMPORTANCE Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with lower risk of colorectal cancer. OBJECTIVE To identify common genetic markers that may confer differential benefit from aspirin or NSAID chemoprevention, we tested gene × environment interactions between regular use of aspirin and/or NSAIDs and single-nucleotide polymorphisms (SNPs) in relation to risk of colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS Case-control study using data from 5 case-control and 5 cohort studies initiated between 1976 and 2003 across the United States, Canada, Australia, and Germany and including colorectal cancer cases (n=8634) and matched controls (n=8553) ascertained between 1976 and 2011. Participants were all of European descent. EXPOSURES Genome-wide SNP data and information on regular use of aspirin and/or NSAIDs and other risk factors. MAIN OUTCOMES AND MEASURES Colorectal cancer. RESULTS Regular use of aspirin and/or NSAIDs was associated with lower risk of colorectal cancer (prevalence, 28%vs 38%; odds ratio [OR], 0.69 [95%CI, 0.64-0.74]; P = 6.2 × 10-28) compared with nonregular use. In the conventional logistic regression analysis, the SNP rs2965667 at chromosome 12p12.3 near the MGST1 gene showed a genome-wide significant interaction with aspirin and/or NSAID use (P = 4.6 × 10-9 for interaction). Aspirin and/or NSAID use was associated with a lower risk of colorectal cancer among individuals with rs2965667-TT genotype (prevalence, 28%vs 38%; OR, 0.66 [95%CI, 0.61-0.70]; P = 7.7 × 10-33) but with a higher risk among those with rare (4%) TA or AA genotypes (prevalence, 35%vs 29%; OR, 1.89 [95%CI, 1.27-2.81]; P = .002). In case-only interaction analysis, the SNP rs16973225 at chromosome 15q25.2 near the IL16 gene showed a genome-wide significant interaction with use of aspirin and/or NSAIDs (P = 8.2 × 10-9 for interaction). Regular use was associated with a lower risk of colorectal cancer among individuals with rs16973225-AA genotype (prevalence, 28%vs 38%; OR, 0.66 [95%CI, 0.62-0.71]; P = 1.9 × 10-30) but was not associated with risk of colorectal cancer among those with less common (9%) AC or CC genotypes (prevalence, 36% vs 39%; OR, 0.97 [95%CI, 0.78-1.20]; P = .76). CONCLUSIONS AND RELEVANCE In this genome-wide investigation of gene × environment interactions, use of aspirin and/or NSAIDs was associated with lower risk of colorectal cancer, and this association differed according to genetic variation at 2 SNPs at chromosomes 12 and 15. Validation of these findings in additional populations may facilitate targeted colorectal cancer prevention strategies.",

author = "Hongmei Nan and Hutter, {Carolyn M.} and Yi Lin and Jacobs, {Eric J.} and Ulrich, {Cornelia M.} and Emily White and Baron, {John A.} and Berndt, {Sonja I.} and Hermann Brenner and Katja Butterbach and Caan, {Bette J.} and Campbell, {Peter T.} and Carlson, {Christopher S.} and Graham Casey and Jenny Chang-Claude and Chanock, {Stephen J.} and Michelle Cotterchio and David Duggan and Figueiredo, {Jane C.} and Fuchs, {Charles S.} and Giovannucci, {Edward L.} and Jian Gong and Haile, {Robert W.} and Harrison, {Tabitha A.} and Hayes, {Richard B.} and Michael Hoffmeister and Hopper, {John L.} and Hudson, {Thomas J.} and Jenkins, {Mark A.} and Shuo Jiao and Lindor, {Noralane M.} and Mathieu Lemire and {Le Marchand}, Loic and Newcomb, {Polly A.} and Shuji Ogino and Pflugeisen, {Bethann M.} and Potter, {John D.} and Conghui Qu and Rosse, {Stephanie A.} and Anja Rudolph and Schoen, {Robert E.} and Schumacher, {Fredrick R.} and Daniela Seminara and Slattery, {Martha L.} and Thibodeau, {Stephen N.} and Fridtjof Thomas and Mark Thornquist and Warnick, {Greg S.} and Zanke, {Brent W.} and Gauderman, {W. James} and Ulrike Peters and Li Hsu and Chan, {Andrew T.}",

year = "2015",

month = mar,

day = "17",

doi = "10.1001/jama.2015.1815",

language = "English (US)",

volume = "313",

pages = "1133--1142",

journal = "JAMA - Journal of the American Medical Association",

issn = "0002-9955",

publisher = "American Medical Association",

number = "11",

}

TY - JOUR

T1 - Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants

AU - Nan, Hongmei

AU - Hutter, Carolyn M.

AU - Lin, Yi

AU - Jacobs, Eric J.

AU - Ulrich, Cornelia M.

AU - White, Emily

AU - Baron, John A.

AU - Berndt, Sonja I.

AU - Brenner, Hermann

AU - Butterbach, Katja

AU - Caan, Bette J.

AU - Campbell, Peter T.

AU - Carlson, Christopher S.

AU - Casey, Graham

AU - Chang-Claude, Jenny

AU - Chanock, Stephen J.

AU - Cotterchio, Michelle

AU - Duggan, David

AU - Figueiredo, Jane C.

AU - Fuchs, Charles S.

AU - Giovannucci, Edward L.

AU - Gong, Jian

AU - Haile, Robert W.

AU - Harrison, Tabitha A.

AU - Hayes, Richard B.

AU - Hoffmeister, Michael

AU - Hopper, John L.

AU - Hudson, Thomas J.

AU - Jenkins, Mark A.

AU - Jiao, Shuo

AU - Lindor, Noralane M.

AU - Lemire, Mathieu

AU - Le Marchand, Loic

AU - Newcomb, Polly A.

AU - Ogino, Shuji

AU - Pflugeisen, Bethann M.

AU - Potter, John D.

AU - Qu, Conghui

AU - Rosse, Stephanie A.

AU - Rudolph, Anja

AU - Schoen, Robert E.

AU - Schumacher, Fredrick R.

AU - Seminara, Daniela

AU - Slattery, Martha L.

AU - Thibodeau, Stephen N.

AU - Thomas, Fridtjof

AU - Thornquist, Mark

AU - Warnick, Greg S.

AU - Zanke, Brent W.

AU - Gauderman, W. James

AU - Peters, Ulrike

AU - Hsu, Li

AU - Chan, Andrew T.

PY - 2015/3/17

Y1 - 2015/3/17

N2 - IMPORTANCE Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with lower risk of colorectal cancer. OBJECTIVE To identify common genetic markers that may confer differential benefit from aspirin or NSAID chemoprevention, we tested gene × environment interactions between regular use of aspirin and/or NSAIDs and single-nucleotide polymorphisms (SNPs) in relation to risk of colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS Case-control study using data from 5 case-control and 5 cohort studies initiated between 1976 and 2003 across the United States, Canada, Australia, and Germany and including colorectal cancer cases (n=8634) and matched controls (n=8553) ascertained between 1976 and 2011. Participants were all of European descent. EXPOSURES Genome-wide SNP data and information on regular use of aspirin and/or NSAIDs and other risk factors. MAIN OUTCOMES AND MEASURES Colorectal cancer. RESULTS Regular use of aspirin and/or NSAIDs was associated with lower risk of colorectal cancer (prevalence, 28%vs 38%; odds ratio [OR], 0.69 [95%CI, 0.64-0.74]; P = 6.2 × 10-28) compared with nonregular use. In the conventional logistic regression analysis, the SNP rs2965667 at chromosome 12p12.3 near the MGST1 gene showed a genome-wide significant interaction with aspirin and/or NSAID use (P = 4.6 × 10-9 for interaction). Aspirin and/or NSAID use was associated with a lower risk of colorectal cancer among individuals with rs2965667-TT genotype (prevalence, 28%vs 38%; OR, 0.66 [95%CI, 0.61-0.70]; P = 7.7 × 10-33) but with a higher risk among those with rare (4%) TA or AA genotypes (prevalence, 35%vs 29%; OR, 1.89 [95%CI, 1.27-2.81]; P = .002). In case-only interaction analysis, the SNP rs16973225 at chromosome 15q25.2 near the IL16 gene showed a genome-wide significant interaction with use of aspirin and/or NSAIDs (P = 8.2 × 10-9 for interaction). Regular use was associated with a lower risk of colorectal cancer among individuals with rs16973225-AA genotype (prevalence, 28%vs 38%; OR, 0.66 [95%CI, 0.62-0.71]; P = 1.9 × 10-30) but was not associated with risk of colorectal cancer among those with less common (9%) AC or CC genotypes (prevalence, 36% vs 39%; OR, 0.97 [95%CI, 0.78-1.20]; P = .76). CONCLUSIONS AND RELEVANCE In this genome-wide investigation of gene × environment interactions, use of aspirin and/or NSAIDs was associated with lower risk of colorectal cancer, and this association differed according to genetic variation at 2 SNPs at chromosomes 12 and 15. Validation of these findings in additional populations may facilitate targeted colorectal cancer prevention strategies.

AB - IMPORTANCE Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with lower risk of colorectal cancer. OBJECTIVE To identify common genetic markers that may confer differential benefit from aspirin or NSAID chemoprevention, we tested gene × environment interactions between regular use of aspirin and/or NSAIDs and single-nucleotide polymorphisms (SNPs) in relation to risk of colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS Case-control study using data from 5 case-control and 5 cohort studies initiated between 1976 and 2003 across the United States, Canada, Australia, and Germany and including colorectal cancer cases (n=8634) and matched controls (n=8553) ascertained between 1976 and 2011. Participants were all of European descent. EXPOSURES Genome-wide SNP data and information on regular use of aspirin and/or NSAIDs and other risk factors. MAIN OUTCOMES AND MEASURES Colorectal cancer. RESULTS Regular use of aspirin and/or NSAIDs was associated with lower risk of colorectal cancer (prevalence, 28%vs 38%; odds ratio [OR], 0.69 [95%CI, 0.64-0.74]; P = 6.2 × 10-28) compared with nonregular use. In the conventional logistic regression analysis, the SNP rs2965667 at chromosome 12p12.3 near the MGST1 gene showed a genome-wide significant interaction with aspirin and/or NSAID use (P = 4.6 × 10-9 for interaction). Aspirin and/or NSAID use was associated with a lower risk of colorectal cancer among individuals with rs2965667-TT genotype (prevalence, 28%vs 38%; OR, 0.66 [95%CI, 0.61-0.70]; P = 7.7 × 10-33) but with a higher risk among those with rare (4%) TA or AA genotypes (prevalence, 35%vs 29%; OR, 1.89 [95%CI, 1.27-2.81]; P = .002). In case-only interaction analysis, the SNP rs16973225 at chromosome 15q25.2 near the IL16 gene showed a genome-wide significant interaction with use of aspirin and/or NSAIDs (P = 8.2 × 10-9 for interaction). Regular use was associated with a lower risk of colorectal cancer among individuals with rs16973225-AA genotype (prevalence, 28%vs 38%; OR, 0.66 [95%CI, 0.62-0.71]; P = 1.9 × 10-30) but was not associated with risk of colorectal cancer among those with less common (9%) AC or CC genotypes (prevalence, 36% vs 39%; OR, 0.97 [95%CI, 0.78-1.20]; P = .76). CONCLUSIONS AND RELEVANCE In this genome-wide investigation of gene × environment interactions, use of aspirin and/or NSAIDs was associated with lower risk of colorectal cancer, and this association differed according to genetic variation at 2 SNPs at chromosomes 12 and 15. Validation of these findings in additional populations may facilitate targeted colorectal cancer prevention strategies.

UR - http://www.scopus.com/inward/record.url?scp=84929390853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929390853&partnerID=8YFLogxK

U2 - 10.1001/jama.2015.1815

DO - 10.1001/jama.2015.1815

M3 - Article

C2 - 25781442

AN - SCOPUS:84929390853

SN - 0002-9955

VL - 313

SP - 1133

EP - 1142

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

IS - 11

ER -

Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this